Korea FDA Approves Roche's Herceptin For First-line Metastatic Gastric Cancer
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea FDA approved Roche's targeted anti-cancer drug Herceptin (trastuzumab) for first-line treatment of HER2-positive metastatic gastric cancer, providing a targeted therapy for the most common and leading cancer in Korea